The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Concise Drug Review: Azacitidine and Decitabine
Open accessAbstract
The introduction of the hypomethylating agents azacitidine and decitabine has been a major advancement in the treatment of patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia who are ineligible for more intensive treatments. This concise drug review summarizes the current state of treatment with azacitidine and decitabine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663 · cited 7×
“Themedian durationof thehematological responsewas about 13months in both azacitidine studies [2, 14, 15] and 9–10months in both decitabine studies [4, 5].”
BackgroundResultInfluentialSilverman, L. R., Demakos, E. P., Peterson, B. L., Kornblith, A. B., Holland, J. C., Odchimar-Reissig, R., Stone, R. M., Nelson, D., Powell, B. L., DeCastro, C. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.117 · Cited by 1,825
Cheson, B. D. (2006) · Blood · doi:10.1182/blood-2005-10-4149 · Cited by 1,580
Kantarjian, H., Issa, J. J., Rosenfeld, C. S., Bennett, J. M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F., et al. (2006) · Cancer · doi:10.1002/cncr.21792 · Cited by 1,530
Christman, J. K. (2002) · Oncogene · doi:10.1038/sj.onc.1205699 · Cited by 1,525
Kantarjian, H. M., Thomas, X. G., Dmoszynska, A., Wierzbowska, A., Mazur, G., Mayer, J., Gau, J.-P., Chou, W.-C., Buckstein, R., Cermak, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9429 · Cited by 1,169
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine
Stresemann, C., & Lyko, F. (2008) · International Journal of Cancer · doi:10.1002/ijc.23607 · Cited by 949
Silverman, L. R., McKenzie, D. R., Peterson, B. L., Holland, J. F., Backstrom, J. T., Beach, C. L., & Larson, R. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4346 · Cited by 552
Lübbert, M., Suciu, S., Baila, L., Rüter, B. H., Platzbecker, U., Giagounidis, A., Selleslag, D., Labar, B., Germing, U., Salih, H. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.9245 · Cited by 552
Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
Prébet, T., Gore, S. D., Esterni, B., Gardin, C., Itzykson, R., Thepot, S., Dreyfus, F., Rauzy, O. B., Recher, C., Adès, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.8135 · Cited by 475
Itzykson, R., Kosmider, O., Cluzeau, T., Mansat-De Mas, V, Dreyfus, F., Beyne-Rauzy, O., Quesnel, B., Vey, N., Gelsi-Boyer, V, Raynaud, S., et al. (2011) · Leukemia · doi:10.1038/leu.2011.71 · Cited by 471
Issa, J.-P. J., & Kantarjian, H. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2783 · Cited by 446
Itzykson, R., Thépot, S., Quesnel, B., Dreyfus, F., Beyne-Rauzy, O., Turlure, P., Vey, N., Recher, C., Dartigeas, C., Legros, L., et al. (2011) · Blood · doi:10.1182/blood-2010-06-289280 · Cited by 383
Steensma, D. P., Baer, M. R., Slack, J. L., Buckstein, R., Godley, L. A., Garcia-Manero, G., Albitar, M., Larsen, J. S., Arora, S., Cullen, M. T., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6550 · Cited by 319
Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy
Jabbour, E., Garcia‐Manero, G., Batty, N., Shan, J., O'Brien, S., Cortes, J., Ravandi, F., Issa, J., & Kantarjian, H. (2010) · Cancer · doi:10.1002/cncr.25247 · Cited by 276
Lyons, R. M., Cosgriff, T. M., Modi, S. S., Gersh, R. H., Hainsworth, J. D., Cohn, A. L., McIntyre, H. J., Fernando, I. J., Backstrom, J. T., & Beach, C. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.1058 · Cited by 274
Cancer DNA Methylation: Molecular Mechanisms and Clinical Implications
McCabe, M. T., Brandes, J. C., & Vertino, P. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2784 · Cited by 263
Quintás-Cardama, A., Ravandi, F., Liu-Dumlao, T., Brandt, M., Faderl, S., Pierce, S., Borthakur, G., Garcia-Manero, G., Cortes, J., & Kantarjian, H. (2012) · Blood · doi:10.1182/blood-2012-06-436055 · Cited by 218
Silverman, L. R., Fenaux, P., Mufti, G. J., Santini, V., Hellström‐Lindberg, E., Gattermann, N., Sanz, G., List, A. F., Gore, S. D., & Seymour, J. F. (2011) · Cancer · doi:10.1002/cncr.25774 · Cited by 194
Sekeres, M. A., Tiu, R. V., Komrokji, R. S., Lancet, J. E., Advani, A. S., Afable, M. G., Englehaupt, R. K., Juersivich, J., Cuthbertson, D. D., Paleveda, J., et al. (2012) · Blood · doi:10.1182/blood-2012-06-434639 · Cited by 141
Santini, V., Fenaux, P., Mufti, G. J., Hellström‐Lindberg, E., Silverman, L. R., List, A. F., Gore, S. D., Seymour, J. F., Backstrom, J. T., & Beach, C. L. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01456.x · Cited by 133
Kantarjian, H. M., O'Brien, S. M., Shan, J., Aribi, A. M., Garcia‐Manero, G., Jabbour, E. J., Ravandi, F., Cortes, J. E., Davisson, J., & Issa, J. J. (2006) · Cancer · doi:10.1002/cncr.22376 · Cited by 115
Epigenetic Changes in the Myelodysplastic Syndrome
Issa, J. J. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.02.007 · Cited by 110
van der Helm, L. H., Alhan, C., Wijermans, P., Kooy, M. V. M., Schaafsma, R., Biemond, B. J., Beeker, A., Hoogendoorn, M., van Rees, B. P., de Weerdt, O., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08893.x · Cited by 108
Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine
Borthakur, G. M., Ahdab, S. E., Ravandi, F., Faderl, S. H., Ferrajoli, A., Newman, B., Issa, J. J., & Kantarjian, H. M. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701882146 · Cited by 103
Cashen, A. F., Shah, A. K., Todt, L. M., Fisher, N. M., & DiPersio, J. F. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0531-7 · Cited by 98
Superiority of prolonged low‐dose azanucleoside administration?
Rüter, B. H., Wijermans, P., & Lübbert, M. (2006) · Cancer · doi:10.1002/cncr.21796 · Cited by 63
Prébet, T., Gore, S. D., Thépot, S., Esterni, B., Quesnel, B., Beyne‐Rauzy, O., Dreyfus, F., Gardin, C., Fenaux, P., & Vey, N. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09076.x · Cited by 56
Zhao, M., Rudek, M. A., He, P., Hartke, C., Gore, S. D., Carducci, M. A., & Baker, S. D. (2004) · Journal of Chromatography B · doi:10.1016/j.jchromb.2004.09.012 · Cited by 43
Patel, K., Guichard, S. M., & Jodrell, D. I. (2008) · Journal of Chromatography B · doi:10.1016/j.jchromb.2007.12.014 · Cited by 30
Breccia, M., Loglisci, G., Cannella, L., Finsinger, P., Mancini, M., Serrao, A., Santopietro, M., Salaroli, A., & Alimena, G. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.643408 · Cited by 23
Optimizing hypomethylating agents in myelodysplastic syndromes
Itzykson, R., & Fenaux, P. (2012) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32834ff58a · Cited by 20
In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine
Chen, Y., Liu, L., Laille, E. J., Kumar, G. N., & Surapaneni, S. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1245-9 · Cited by 12
Cited by
DiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825
Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
Epigenetic Therapies for Cancer
Bates, S. E. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1805035 · Cited by 493
Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy
Biswas, S., & Rao, C. M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.08.021 · Cited by 389
Methylation-Based Therapies for Colorectal Cancer
Cervena, K., Siskova, A., Buchler, T., Vodicka, P., & Vymetalkova, V. (2020) · Cells · doi:10.3390/cells9061540 · Cited by 57
Metadata
- Authors
- Derissen, E. J. B., Beijnen, J. H., & Schellens, J. H. M.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-05-01
- Volume
- 18
- Issue
- 5
- Pages
- 619-624
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2127289529
- Cited by
- 299
- References
- 33
- FWCI
- 9.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.